MX367279B - Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida. - Google Patents

Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida.

Info

Publication number
MX367279B
MX367279B MX2015003061A MX2015003061A MX367279B MX 367279 B MX367279 B MX 367279B MX 2015003061 A MX2015003061 A MX 2015003061A MX 2015003061 A MX2015003061 A MX 2015003061A MX 367279 B MX367279 B MX 367279B
Authority
MX
Mexico
Prior art keywords
mhc class
cell receptors
mage
restricted
receptors recognizing
Prior art date
Application number
MX2015003061A
Other languages
English (en)
Other versions
MX2015003061A (es
Inventor
F Robbins Paul
A Rosenberg Steven
Yao Xin
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MX2015003061A publication Critical patent/MX2015003061A/es
Publication of MX367279B publication Critical patent/MX367279B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G01N33/575—
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)

Abstract

La presente invención se refiere a un receptor de la célula T purificada o aislada (TCR) teniendo especificidad antigénica para MHC de MAGE-A3 de Clase II restringida. La invención además proporciona polipéptidos y proteínas relacionados, así como ácidos nucleicos, vectores de expresión recombinante, células huéspedes y poblaciones de células. Además se proporcionan en la invención anticuerpos o una porción de unión al antígeno de los mismos y composiciones farmacéuticas relacionas a los TCRs de la invención. Además se proporcionan en la invención los métodos para la detección de la presencia de cáncer en un huésped y los métodos para tratar o prevenir el cáncer en un mamífero.
MX2015003061A 2012-09-14 2013-09-13 Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida. MX367279B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261701056P 2012-09-14 2012-09-14
PCT/US2013/059608 WO2014043441A1 (en) 2012-09-14 2013-09-13 T cell receptors recognizing mhc class ii-restricted mage-a3

Publications (2)

Publication Number Publication Date
MX2015003061A MX2015003061A (es) 2015-11-06
MX367279B true MX367279B (es) 2019-08-13

Family

ID=49253425

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015003061A MX367279B (es) 2012-09-14 2013-09-13 Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida.
MX2019009641A MX2019009641A (es) 2012-09-14 2015-03-10 Receptores de la celula t que reconocen mhc de mage-a3 de clase ii-restringida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019009641A MX2019009641A (es) 2012-09-14 2015-03-10 Receptores de la celula t que reconocen mhc de mage-a3 de clase ii-restringida.

Country Status (20)

Country Link
US (4) US9879065B2 (es)
EP (3) EP2895509B1 (es)
JP (4) JP6461796B2 (es)
KR (4) KR102370307B1 (es)
CN (2) CN113754755A (es)
AU (4) AU2013315391B2 (es)
CA (1) CA2884743C (es)
CY (1) CY1122720T1 (es)
DK (2) DK3636665T3 (es)
ES (2) ES2925307T3 (es)
HR (1) HRP20200325T1 (es)
HU (1) HUE048014T2 (es)
IL (3) IL286786B (es)
LT (1) LT2895509T (es)
MX (2) MX367279B (es)
PL (1) PL2895509T3 (es)
PT (1) PT2895509T (es)
SI (1) SI2895509T1 (es)
SM (1) SMT202000103T1 (es)
WO (1) WO2014043441A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102370307B1 (ko) * 2012-09-14 2022-03-04 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Mhc ii형 제한된 mage-a3을 인식하는 t 세포 수용체
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
WO2016053339A1 (en) 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells having antigenic specificity for a cancer-specific mutation
AU2014407539B2 (en) * 2014-10-02 2020-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
CN109265517B (zh) * 2015-03-27 2024-05-10 伊玛提克斯生物技术有限公司 用于各种肿瘤免疫治疗的肽和肽组合物
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
WO2017142988A1 (en) * 2016-02-18 2017-08-24 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating melanoma
GB201604494D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
LT3430037T (lt) * 2016-03-16 2022-12-12 Immatics Biotechnologies Gmbh Transfekuotos t ląstelės ir t ląstelių receptoriai, skirti naudoti vėžio gydymui taikant imunoterapiją
CN106749620B (zh) * 2016-03-29 2020-09-25 广东香雪精准医疗技术有限公司 识别mage-a1抗原短肽的t细胞受体
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2018097951A1 (en) 2016-11-22 2018-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3/a6 antibodies
DE102016123859B3 (de) 2016-12-08 2018-03-01 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
CN108250289B (zh) * 2016-12-28 2021-10-08 香雪生命科学技术（广东）有限公司 源自于mage b6的肿瘤抗原短肽
CA3049244A1 (en) 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
CN110612119B (zh) 2017-02-07 2024-10-29 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
MA50748A (fr) * 2017-10-05 2020-08-12 Us Health Méthodes d'expansion sélective de cellules exprimant un tcr avec une région constante murine
WO2019075055A1 (en) 2017-10-11 2019-04-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR PRODUCING T-CELL POPULATIONS USING P38 MAPK INHIBITORS
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
CN109837248A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种tcr敲除的靶向mage-a3的t细胞受体基因修饰t细胞及其制备方法和应用
CN109836490A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向mage-a3的t细胞受体、t细胞受体基因修饰t细胞及其制备方法和应用
CN120154716A (zh) 2018-01-22 2025-06-17 恩多塞特公司 Car t细胞的使用方法
CN111936518A (zh) 2018-02-06 2020-11-13 西雅图儿童医院（Dba西雅图儿童研究所） 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
US20210052647A1 (en) 2018-02-09 2021-02-25 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Tethered interleukin-15 and interleukin-21
TW202000229A (zh) 2018-02-23 2020-01-01 美商安德賽特公司 Car t細胞療法之順序方法
WO2019204683A1 (en) * 2018-04-19 2019-10-24 Board Of Regents, The University Of Texas System T cell receptors with mage-b2 specificity and uses thereof
CA3097858A1 (en) 2018-04-24 2019-10-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using hydroxycitric acid and/or a salt thereof
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
KR20220075210A (ko) * 2019-07-15 2022-06-07 네오진 테라퓨틱스 비.브이. Tcr 유전자를 단리하기 위한 방법
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
JP2020143057A (ja) * 2020-04-01 2020-09-10 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
JP2023540361A (ja) 2020-09-08 2023-09-22 アメリカ合衆国 養子細胞療法に対する応答に関連するｔ細胞表現型
EP4243937A2 (en) 2020-11-13 2023-09-20 The United States of America, as represented by the Secretary, Department of Health and Human Services Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
JP2025501259A (ja) 2021-12-31 2025-01-17 アメリカ合衆国 がんに対する組合せ免疫療法としてのワクチン接種を伴うｔ細胞療法
CN116813744B (zh) * 2023-02-23 2024-02-23 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025160480A1 (en) 2024-01-26 2025-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
WO2025250587A1 (en) 2024-05-29 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug-regulatable, inducible cytokine expression

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IN165717B (es) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
EP2598528A1 (en) * 2010-07-28 2013-06-05 Immunocore Ltd. T cell receptors
CA2812153C (en) * 2010-09-20 2020-06-30 Biontech Ag Antigen-specific t cell receptors and t cell epitopes
WO2012054825A1 (en) * 2010-10-22 2012-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3 t cell receptors and related materials and methods of use
CN102251033B (zh) * 2011-07-05 2013-03-20 北京大学人民医院 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
AU2012309830B2 (en) 2011-09-15 2017-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing HLA-A1- or HLA-Cw7-restricted mage
US9413985B2 (en) * 2012-09-12 2016-08-09 Lattice Semiconductor Corporation Combining video and audio streams utilizing pixel repetition bandwidth
KR102370307B1 (ko) * 2012-09-14 2022-03-04 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Mhc ii형 제한된 mage-a3을 인식하는 t 세포 수용체

Also Published As

Publication number Publication date
DK3636665T3 (da) 2022-10-03
AU2013315391A1 (en) 2015-04-02
CA2884743C (en) 2023-03-14
US20150246959A1 (en) 2015-09-03
AU2019213329A1 (en) 2019-08-29
JP6461796B2 (ja) 2019-01-30
AU2019213329B2 (en) 2021-03-11
US10611815B2 (en) 2020-04-07
EP2895509B1 (en) 2019-12-04
MX2019009641A (es) 2019-11-28
CN104968675A (zh) 2015-10-07
AU2017219019B2 (en) 2019-05-09
IL274003A (en) 2020-05-31
KR102303166B1 (ko) 2021-09-17
IL286786B (en) 2022-09-01
KR20200118248A (ko) 2020-10-14
PT2895509T (pt) 2020-03-13
CA2884743A1 (en) 2014-03-20
JP6728326B2 (ja) 2020-07-22
US20200270329A1 (en) 2020-08-27
HRP20200325T1 (hr) 2020-06-12
IL274003B (en) 2021-10-31
KR20210114563A (ko) 2021-09-23
HUE048014T2 (hu) 2020-05-28
EP4159753A1 (en) 2023-04-05
LT2895509T (lt) 2020-03-25
AU2021203746B2 (en) 2024-05-02
CN113754755A (zh) 2021-12-07
IL286786A (en) 2021-10-31
AU2013315391B2 (en) 2017-06-08
JP6923714B2 (ja) 2021-08-25
SMT202000103T1 (it) 2020-05-08
PL2895509T3 (pl) 2020-07-27
CY1122720T1 (el) 2021-03-12
KR102480188B1 (ko) 2022-12-21
MX2015003061A (es) 2015-11-06
US20230089465A1 (en) 2023-03-23
AU2021203746A1 (en) 2021-07-01
JP2020178702A (ja) 2020-11-05
AU2017219019A1 (en) 2017-09-14
JP7270001B2 (ja) 2023-05-09
WO2014043441A1 (en) 2014-03-20
EP3636665B1 (en) 2022-06-29
EP3636665A1 (en) 2020-04-15
ES2925307T3 (es) 2022-10-14
IL237560A0 (en) 2015-04-30
CN104968675B (zh) 2021-09-24
KR20220031941A (ko) 2022-03-14
KR20150052086A (ko) 2015-05-13
JP2015535816A (ja) 2015-12-17
JP2019088286A (ja) 2019-06-13
ES2774931T3 (es) 2020-07-23
JP2021191265A (ja) 2021-12-16
US20180127479A1 (en) 2018-05-10
KR102370307B1 (ko) 2022-03-04
EP2895509A1 (en) 2015-07-22
DK2895509T3 (da) 2020-03-09
KR102165350B1 (ko) 2020-10-14
IL237560B (en) 2020-05-31
US12404317B2 (en) 2025-09-02
SI2895509T1 (sl) 2020-04-30
US9879065B2 (en) 2018-01-30

Similar Documents

Publication Publication Date Title
MX367279B (es) Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida.
MX2020005765A (es) Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
MX2020003117A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
MX2020003504A (es) Receptores de celulas t que reconocen p53 mutado.
MX2018003062A (es) Receptores de celula t que reconocen kras mutante restringido en hla-cw8.
CA2848209C (en) T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
MX2016015383A (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
MX2017006865A (es) Receptores de células t de kras anti-mutado.
CO2021012587A2 (es) Receptores de células t mage a4
MX395287B (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
BR112021026408A2 (pt) Receptores de célula t que reconhecem a mutação r175h ou y220c em p53
CY1121466T1 (el) Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης
BR112014008849A2 (pt) receptores quiméricos de antígeno anti-cd22
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
EA201590545A1 (ru) Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией
MX2012003058A (es) Vacunas dirigidas a celulas de langerhans.
MX2016008076A (es) Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
WO2016077525A3 (en) Human anti-thyroglobulin t cell receptors
AR088245A1 (es) Caracterizacion de la proteina y el gen cho-mif y uso de los mismos
CR20150477A (es) Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso
ECSP14024494A (es) Anticuerpos frente a los Ligandos del receptor B1 de bradicinina
AR098848A1 (es) Receptores de antígeno quimérico de mesotelina humana y usos de los mismos

Legal Events

Date Code Title Description
FG Grant or registration